SCHEDULE: Aquamarine Financial Discloses 5.06% Stake in Oramed Pharmaceuticals

Aquamarine Financial (Cayman) Ltd has reported beneficial ownership of 2,047,652 shares, representing 5.06% of Oramed Pharmaceuticals Inc.'s common stock, as of January 14, 2026.

Summary

• Aquamarine Financial (Cayman) Ltd has filed a Schedule 13G, indicating it beneficially owns 2,047,652 shares of Oramed Pharmaceuticals Inc. common stock.
• This ownership stake represents 5.06% of the total class of securities.
• The filing date for this event is January 14, 2026.
• Aquamarine Financial holds sole voting power and sole dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it reports a change in beneficial ownership rather than company performance or strategic shifts. The score reflects the factual nature of the disclosure.

Positives

• Aquamarine Financial has established a significant ownership position in Oramed Pharmaceuticals, crossing the 5% threshold which may signal confidence in the company's future prospects.
• The reporting entity, Aquamarine Financial (Cayman) Ltd, is a Cayman Islands-based entity, suggesting potential international investment interest in Oramed Pharmaceuticals.

Future Outlook

The filing does not contain forward-looking statements or guidance from Oramed Pharmaceuticals. It solely reports on Aquamarine Financial's ownership stake.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders acquiring more than 5% of a public company's stock. This filing indicates Aquamarine Financial's substantial interest in Oramed Pharmaceuticals, a biotechnology company.

Stakeholder Impact

• Shareholders may see this as a sign of increased institutional interest in Oramed Pharmaceuticals, potentially leading to greater market attention or volatility.
• The company's management and board may need to engage with Aquamarine Financial given their significant ownership stake.

Key Dates

Keywords

Oramed Pharmaceuticals, Aquamarine Financial, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Cayman Islands